Valuation : Seres Therapeutics, Inc.

Market Cap 50.8M 43.77M 41.04M 37.47M 70.58M 4.86B 70.8M 487M 190M 2.45B 191M 187M 8.13B P/E 2026 *
-1.45x
P/E 2027 * -1.03x
Enterprise Value 50.8M 43.77M 41.04M 37.47M 70.58M 4.86B 70.8M 487M 190M 2.45B 191M 187M 8.13B EV / Sales 2026 *
3.68x
EV / Sales 2027 * 186x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Seres Therapeutics, Inc.

1 day+3.23%
1 week+12.06%
Current month+5.80%
1 month+9.89%
3 months-30.19%
6 months-41.53%
Current year-65.66%
1 week 4.44
Extreme 4.4356
5.15
1 month 4.32
Extreme 4.315
5.65
Current year 4.32
Extreme 4.315
16.42
1 year 4.32
Extreme 4.315
29.98
3 years 4.32
Extreme 4.315
73.4
5 years 4.32
Extreme 4.315
233.8
10 years 4.32
Extreme 4.315
770
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2026
Chief Executive Officer 58 31/07/2025
President 51 01/03/2026
Director TitleAgeSince
Chairman 70 01/03/2026
Director/Board Member 50 14/01/2019
Director/Board Member 80 31/03/2015
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Sell

General Counsel

-82 0.0008%
17/08/26 Sell

Director

-263 0.0027%
17/08/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
+3.23%+12.06%-73.02%-92.82% 50.8M
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.50%-0.53%+44.69%+163.09% 28.2B
Weighted average by Cap. -1.93%-1.50%+53.70%+151.47%

Financials

2026 *2027 *
Net sales 13.8M 11.89M 11.15M 10.18M 19.17M 1.32B 19.23M 132M 51.6M 666M 51.8M 50.67M 2.21B 274K 236K 221K 202K 380K 26.14M 381K 2.62M 1.02M 13.2M 1.03M 1M 43.75M
Net income -37.49M -32.3M -30.29M -27.65M -52.09M -3.58B -52.25M -359M -140M -1.81B -141M -138M -6B -78.95M -68.04M -63.79M -58.23M -110M -7.55B -110M -757M -295M -3.81B -296M -290M -12.63B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
28/08/26 US$5.110 +3.23% 32,490
27/08/26 US$4.950 +3.99% 22,869
26/08/26 US$4.760 -4.80% 58,204
25/08/26 US$5.000 +7.30% 102,958
24/08/26 US$4.660 +2.19% 74,812
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.110USD
Average target price
17.00USD
Spread / Average Target
+232.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock